文献速递泌尿生殖与妇科肿瘤放疗

高危与极高危非转移性前列腺癌择区盆腔放疗的作用回顾性分析

Examining the role of elective pelvic radiotherapy in patients Diagnosed with high- and very High-Risk Non-Metastatic prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-04-11

该回顾性研究纳入434例接受根治性放疗的高危(HR)和极高危(VHR)非转移性前列腺癌患者,比较全盆腔放疗(WPRT)与仅前列腺放疗(PORT)的生存结局。VHR亚组中WPRT在BRFS、DMFS、DFS和FFS上显著优于PORT,OS呈利于WPRT的趋势;HR组两组间无显著生存差异。结论认为HR患者可省略择区盆腔照射,尤其70岁以上者;VHR患者即使老年也应考虑择区盆腔照射。

要点

  • VHR亚组WPRT较PORT显著改善5年BRFS、DMFS、DFS和FFS,OS呈利于WPRT趋势。
  • HR组WPRT与PORT在各生存终点上均无显著差异。
  • HR患者可省略择区盆腔照射,尤其70岁以上;VHR患者即使老年也应考虑择区盆腔照射。

核心结论

  • 基于本回顾性数据,HR患者可省略择区盆腔照射,尤其70岁以上者。
  • 对于VHR患者,即使老年亚组也应考虑择区盆腔照射。

研究设计与样本

  • 回顾性分析434例接受根治性放疗的淋巴结阴性、非转移性HR和VHR前列腺癌患者。
  • PORT组203例(HR 127例,VHR 76例),WPRT组231例(HR 113例,VHR 118例),均接受前列腺加量。
  • 患者接受2-3年雄激素剥夺治疗;PORT组平均年龄73.9±4.3岁,WPRT组66.4±5.4岁。
  • 采用逆倾向评分加权构建WPRT与PORT组间T分期、PSA和Gleason评分均衡(但年龄未均衡)的同质队列。
  • 采用Kaplan-Meier法和Cox回归比较BRFS、LRFS、RRFS、DMFS、DFS、FFS和OS。

主要发现

  • 中位随访76个月(范围3-134个月)。
  • VHR亚组5年BRFS:WPRT组82.2% vs PORT组73%(p=0.028),WPRT组显著更优。
  • VHR亚组5年DMFS:WPRT组87.5% vs PORT组73.6%(p=0.025),WPRT组显著更优。
  • VHR亚组5年DFS:WPRT组86.1% vs PORT组70.5%(p=0.012),WPRT组显著更优;FFS:WPRT组82.3% vs PORT组68.9%(p=0.005),WPRT组显著更优。
  • VHR亚组OS:WPRT组92.8% vs PORT组81.8%(p=0.056),呈利于WPRT组的趋势;LRFS和RRFS两组无显著差异。

关键数值与推荐

  • VHR亚组5年BRFS:WPRT组82.2% vs PORT组73%(p=0.028)。
  • VHR亚组5年DMFS:WPRT组87.5% vs PORT组73.6%(p=0.025)。
  • VHR亚组5年DFS:WPRT组86.1% vs PORT组70.5%(p=0.012);FFS:WPRT组82.3% vs PORT组68.9%(p=0.005)。
  • VHR亚组5年OS:WPRT组92.8% vs PORT组81.8%(p=0.056)。
  • HR组各终点WPRT vs PORT均无显著差异(p值范围0.120-0.978)。

临床怎么用

  • HR患者可省略择区盆腔照射,尤其70岁以上者。
  • VHR患者即使老年也应考虑择区盆腔照射。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the treatment of node-negative, non-metastatic high-risk (HR) and very high-risk (VHR) prostate cancer, the necessity of elective pelvic irradiation is controversial. According to our in-house treatment protocol - elective pelvic irradiation is generally omitted for HR and VHR patients over the age of 70 or those in poor general health due to its toxicity. OBJECTIVE: To retrospectively examine the outcome for HR and VHR prostate cancer patients treated with elective whole pelvic radiotherapy (WPRT) versus prostate-only radiotherapy (PORT). MATERIALS AND METHODS: The study included 434 patients treated with definitive radiotherapy, 203 patients received PORT (HR: 127, VHR: 76) and 231 WPRT (HR: 113, VHR: 118) with a boost to the prostate. Patients also received 2-3 years of androgen deprivation. Patients' average age who received PORT vs. WPRT was 73.9 ± 4.3 years vs. 66.4 ± 5.4 years respectively. An inverse propensity score weighting method was utilized to create homogeneous WPRT and PORT treatment groups that are balanced for T stage, PSA, and Gleason score, but not for age. The survival outcomes for HR and VHR subgroups were examined depending on whether they received WPRT or PORT. Biochemical- (BRFS), local- (LRFS) and regional relapse-free survival (RRFS), distant metastasis-free- (DMFS), disease-free- (DFS), failure-free- (FFS), and overall survival (OS) were compared using the Kaplan -Meier method and Cox regression analysis. RESULTS: The median follow-up time was 76 months (3-134 months). In the VHR subgroup five-year outcomes showed a significant advantage for patients receiving WPRT vs. PORT in BRFS (82.2 % vs. 73 %; p = 0.028), in DMFS (87.5 % vs. 73.6 %; p = 0.025), in DFS (86.1 % vs. 70.5 %; p = 0.012), and in FFS (82.3 % vs. 68.9 %; p = 0.005), respectively. The OS (92.8 % vs. 81.8 %; p = 0.056) showed a trend favoring the WPRT group. There was no significant difference between WPRT vs. PORT in LRFS (95.8 % vs. 96.4 %; p = 0.763) and RRFS (95.8 % vs. 89.9 %; p = 0.099). On the contrary, in the HR group, no significant survival differences were observed between WPRT vs. PORT groups: BRFS 93.0 % vs. 93.3 % (p = 0.978), LRFS 99.0 % vs. 100 % (p = 0.120), RRFS 98.2 % vs. 95.1 % (p = 0.813), DMFS 93.5 % vs. 95.5 % (p = 0.793), DFS 91.7 % vs. 92.9 % (p = 0.691), FFS 89.5 % vs. 90.9 % (p = 0.853), OS 91.0 % vs. 87.7 % (p = 0.407). CONCLUSION: Based on our retrospective data elective pelvic irradiation can be omitted in HR patients, especially over the age of 70. For VHR patients, elective pelvic irradiation should be considered even for the subgroup of elderly patients.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nahaji I, Kocsis ZS, Kovács A, et al. Examining the role of elective pelvic radiotherapy in patients Diagnosed with high- and very High-Risk Non-Metastatic prostate cancer. Clin Transl Radiat Oncol. 2025. PMID: 40291048. doi:10.1016/j.ctro.2025.100960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。